EarningsApellis reported better-than-expected, positive results for subq pegcetacoplan in two rare, serious kidney diseases (C3G/IC-MPGN).
Market GrowthSyfovre maintained 50% of new patient starts despite being Izervay’s first quarter with a permanent J-code, and Syfovre still maintained 75% share of the total GA market based on number of patients treated.
Regulatory MilestonesAPLS and Sobi announced positive topline results from the Ph3 VALIANT trial of pegcetacoplan in the rare kidney indications C3G & IC-MPGN.